The Board of Eris Lifesciences at its meeting held on 14 March 2024 has approved the following:➢ Agreement to acquire the Branded Formulations businesses of Biocon Biologics pertaining to the Indian Territory to the extent and in the manner mentioned therein.➢ Agreement to acquire 19% equity stake in Swiss Parenterals from the Promoters of the Company.Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 0.86% to Rs 102.74 crore in the quarter ended December 2023 as against Rs 101.86 crore during the previous quarter ended December 2022. Sales rose 15.71% to Rs 483.48 crore in the quarter ended December 2023 as against Rs 417.84 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales483.48417.84 16 OPM %36.3032.84 - PBDT161.59136.44 18 PBT115.87106.54 9 NP102.74101.86 1 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 13 February 2024.Powered by Capital Market - Live News

ERIS Lifesciences has allotted 5032 equity shares under ESOP on 22 December 2023. The paid up share capital of the Company accordingly stands increased from Rs. 13,60,23,248 /- (13,60,23,248 equity shares of Re. 1/- each) to Rs. 13,60,28,280/- (13,60,28,280 equity shares of Re. 1/- each).Powered by Capital Market - Live News

ERIS Lifesciences has completed the acquisition of the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics. Powered by Capital Market - Live News